Citigroup Issues Positive Forecast for Corteva (NYSE:CTVA) Stock Price

Corteva (NYSE:CTVA - Get Free Report) had its price target hoisted by stock analysts at Citigroup from $83.00 to $85.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Citigroup's price target would suggest a potential upside of 7.41% from the company's previous close.

CTVA has been the topic of a number of other research reports. Royal Bank Of Canada raised their target price on Corteva from $89.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, April 24th. Deutsche Bank Aktiengesellschaft lifted their price target on Corteva from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, February 5th. Wolfe Research increased their price target on shares of Corteva from $81.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, February 5th. Wells Fargo & Company raised their price target on shares of Corteva from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 21st. Finally, BNP Paribas Exane increased their price objective on Corteva from $74.00 to $77.00 in a report on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $86.86.

Corteva Stock Down 3.2%

Shares of NYSE CTVA traded down $2.64 during trading on Thursday, hitting $79.14. 6,274,985 shares of the company traded hands, compared to its average volume of 4,024,688. The firm has a market capitalization of $53.13 billion, a price-to-earnings ratio of 46.55, a P/E/G ratio of 2.88 and a beta of 0.59. The business's fifty day moving average is $80.66 and its 200 day moving average is $72.48. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.96 and a current ratio of 1.43. Corteva has a fifty-two week low of $60.53 and a fifty-two week high of $85.63.

Corteva (NYSE:CTVA - Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.18 by $0.32. The company had revenue of $4.91 billion for the quarter, compared to analysts' expectations of $4.64 billion. Corteva had a return on equity of 9.88% and a net margin of 6.50%.Corteva's quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the business earned $1.13 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Equities research analysts predict that Corteva will post 3.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Corteva news, insider Brian Titus sold 8,311 shares of the firm's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the transaction, the insider owned 8,090 shares in the company, valued at $619,289.50. This trade represents a 50.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.15% of the stock is currently owned by corporate insiders.

Institutional Trading of Corteva

Several institutional investors and hedge funds have recently bought and sold shares of the company. Activest Wealth Management raised its position in shares of Corteva by 118.3% in the third quarter. Activest Wealth Management now owns 369 shares of the company's stock worth $25,000 after buying an additional 200 shares in the last quarter. JPL Wealth Management LLC purchased a new stake in shares of Corteva in the 3rd quarter valued at about $25,000. Westfuller Advisors LLC grew its holdings in shares of Corteva by 2,764.3% during the first quarter. Westfuller Advisors LLC now owns 401 shares of the company's stock worth $34,000 after purchasing an additional 387 shares in the last quarter. Garton & Associates Financial Advisors LLC bought a new position in shares of Corteva in the fourth quarter worth approximately $27,000. Finally, Bank of Jackson Hole Trust purchased a new stake in Corteva in the fourth quarter valued at approximately $28,000. 81.54% of the stock is currently owned by hedge funds and other institutional investors.

Corteva News Summary

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Corteva reported a stronger‑than‑expected Q1 (EPS and revenue beats), reaffirmed its 2026 outlook and said it remains on track for the planned 4Q‑2026 separation — fundamental results that support upside. Corteva Agriscience: Corteva Delivers Strong 1Q 2026, Reaffirms 2026 Outlook, On-Track for 4Q 2026 Separation
• Positive Sentiment: Jefferies raised its price target to $97, implying sizable upside versus current levels — a bullish analyst signal that can support the stock. Jefferies adjusts price target on Corteva to $97 from $95
• Neutral Sentiment: Management (CEO Chuck Magro and CFO David Johnson) will present at the BMO Global Farm to Market conference on May 14 — an event where management can reiterate guidance and answer analyst questions, but not an immediate catalyst. Corteva to Participate in BMO Global Farm to Market Conference
• Neutral Sentiment: Transcripts and the earnings presentation are now available for deeper review — useful for investors who want detail on margins, regional demand and guidance drivers. Corteva, Inc. (CTVA) Q1 2026 Earnings Call Transcript
• Negative Sentiment: BNP Paribas Exane lifted its target only to $77, which sits below current market levels and signals some analyst caution about upside from here — a factor contributing to downward pressure. BNP Paribas adjusts price target on Corteva to $77 from $74

About Corteva

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.